XTRA:FREHealthcare
How Fresenius Kabi’s T Cell Automation Deal At Fresenius SE KGaA (XTRA:FRE) Has Changed Its Investment Story
Earlier this week, Fresenius Kabi and TQ Therapeutics announced a development agreement giving Fresenius Kabi exclusive rights to integrate TQ’s proprietary cell selection technology into its Cue Cell Processing System for automated, high‑purity T cell isolation in cell and gene therapy manufacturing.
This collaboration could materially enhance Fresenius’s position in advanced therapies by pairing TQ’s affinity-based cell isolation with Fresenius Kabi’s automation capabilities, potentially...